Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14980593 | 0.95 | CYP2C19 (0.40) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL3972281 | 0.92 | CYP2C19 (0.43) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL8437150 | 0.90 | TSHR (0.46) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL9079152 | 0.90 | CYP2C19 (0.41) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL4192702 | 0.87 | CYP2C19 (0.39) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL250410 | 0.87 | CYP2C19 (0.43) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL13267574 | 0.86 | TSHR (0.50) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL14252331 | 0.86 | CYP2C19 (0.35) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL31273768 | 0.86 | TSHR (0.50) | TSHRCYP2C19MEN1KMT2AGLA | |
| SCHEMBL10144492 | 0.85 | PAOX (0.33) | TSHRCYP2C19MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981435-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | TSHR 344/4885CYP2C19 3249/4885MEN1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.